Sovaldi treats certain types of Hepatitis C viruses without needing to co-administer interferon, according to the news release.
Sovaldi blocks a protein the Hepatitis C virus uses to duplicate itself. The drug should be used as part of a combination antiviral treatment.
This is the second drug in two weeks the FDA has cleared to treat Hepatitis C. The FDA approved Olysio on Nov. 22.
More Articles on the FDA:
4 Latest FDA Approvals
FDA Issues Safety Communication on Certain HeartStart AEDs from Philips Medical Systems
FDA Recalls Spacelabs Healthcare’s Anesthesia Workstations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
